Epigenomics AG (EPGNF)
USD 0.79
(0.0%)
USD 0.79
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 4.78 Million EUR | -63.85% |
| 2022 | 13.22 Million EUR | 29.28% |
| 2021 | 10.22 Million EUR | -5.38% |
| 2020 | 10.81 Million EUR | -32.32% |
| 2019 | 15.97 Million EUR | 11.05% |
| 2018 | 14.38 Million EUR | 25.38% |
| 2017 | 11.47 Million EUR | -23.54% |
| 2016 | 15 Million EUR | 47.34% |
| 2015 | 10.18 Million EUR | 11.75% |
| 2014 | 9.11 Million EUR | 9.74% |
| 2013 | 8.3 Million EUR | -35.4% |
| 2012 | 12.85 Million EUR | -21.26% |
| 2011 | 16.32 Million EUR | 27.92% |
| 2010 | 12.76 Million EUR | 9.26% |
| 2009 | 11.68 Million EUR | -14.36% |
| 2008 | 13.63 Million EUR | 386.93% |
| 2007 | -4.75 Million EUR | 1.47% |
| 2006 | -4.82 Million EUR | 42.09% |
| 2005 | -8.33 Million EUR | -8.25% |
| 2004 | -7.69 Million EUR | -823.77% |
| 2003 | -833 Thousand EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 FY | 4.78 Million EUR | -63.85% |
| 2023 Q4 | 1.84 Million EUR | 0.0% |
| 2023 Q2 | 2.83 Million EUR | -51.82% |
| 2023 Q1 | 5.88 Million EUR | -29.82% |
| 2023 Q3 | 1.84 Million EUR | -35.1% |
| 2022 Q3 | 1.46 Million EUR | -62.58% |
| 2022 Q1 | 3.33 Million EUR | -9.17% |
| 2022 Q4 | 8.39 Million EUR | 471.14% |
| 2022 FY | 13.22 Million EUR | 29.28% |
| 2022 Q2 | 3.92 Million EUR | 17.9% |
| 2021 Q3 | 2.9 Million EUR | 2.29% |
| 2021 Q4 | 3.66 Million EUR | 26.2% |
| 2021 FY | 10.22 Million EUR | -5.38% |
| 2021 Q1 | 2.1 Million EUR | 59.65% |
| 2021 Q2 | 2.84 Million EUR | 34.66% |
| 2020 FY | 10.81 Million EUR | -32.32% |
| 2020 Q3 | 2.91 Million EUR | -21.12% |
| 2020 Q1 | 3.14 Million EUR | -30.15% |
| 2020 Q2 | 3.69 Million EUR | 17.47% |
| 2020 Q4 | 1.32 Million EUR | -54.71% |
| 2019 FY | 15.97 Million EUR | 11.05% |
| 2019 Q1 | 3.55 Million EUR | -20.91% |
| 2019 Q2 | 4.69 Million EUR | 32.08% |
| 2019 Q3 | 2.97 Million EUR | -36.61% |
| 2019 Q4 | 4.5 Million EUR | 51.6% |
| 2018 Q3 | 3.45 Million EUR | 9.13% |
| 2018 FY | 14.38 Million EUR | 25.38% |
| 2018 Q1 | 3.52 Million EUR | 51.05% |
| 2018 Q2 | 3.16 Million EUR | -10.19% |
| 2018 Q4 | 4.49 Million EUR | 29.99% |
| 2017 FY | 11.47 Million EUR | -23.54% |
| 2017 Q1 | 2.94 Million EUR | -11.54% |
| 2017 Q3 | 1.47 Million EUR | -68.85% |
| 2017 Q2 | 4.72 Million EUR | 60.5% |
| 2017 Q4 | 2.33 Million EUR | 58.49% |
| 2016 Q2 | 3.95 Million EUR | -19.17% |
| 2016 FY | 15 Million EUR | 47.34% |
| 2016 Q4 | 3.32 Million EUR | 15.56% |
| 2016 Q3 | 2.88 Million EUR | -27.11% |
| 2016 Q1 | 4.88 Million EUR | 304.64% |
| 2015 Q3 | 2.7 Million EUR | -4.65% |
| 2015 Q4 | 1.2 Million EUR | -55.37% |
| 2015 Q2 | 2.83 Million EUR | -17.25% |
| 2015 Q1 | 3.43 Million EUR | 9.44% |
| 2015 FY | 10.18 Million EUR | 11.75% |
| 2014 Q1 | 2.2 Million EUR | -12.5% |
| 2014 FY | 9.11 Million EUR | 9.74% |
| 2014 Q4 | 3.13 Million EUR | 60.11% |
| 2014 Q3 | 1.95 Million EUR | 7.88% |
| 2014 Q2 | 1.81 Million EUR | -17.69% |
| 2013 Q2 | 1.81 Million EUR | -6.77% |
| 2013 Q3 | 2.01 Million EUR | 10.84% |
| 2013 Q4 | 2.52 Million EUR | 25.06% |
| 2013 FY | 8.3 Million EUR | -35.4% |
| 2013 Q1 | 1.95 Million EUR | -32.85% |
| 2012 Q2 | 3.57 Million EUR | 43.21% |
| 2012 FY | 12.85 Million EUR | -21.26% |
| 2012 Q1 | 2.49 Million EUR | -46.18% |
| 2012 Q3 | 3.88 Million EUR | 8.62% |
| 2012 Q4 | 2.9 Million EUR | -25.17% |
| 2011 FY | 16.32 Million EUR | 27.92% |
| 2011 Q1 | 3.21 Million EUR | -7.91% |
| 2011 Q2 | 3.23 Million EUR | 0.84% |
| 2011 Q3 | 5.23 Million EUR | 61.65% |
| 2011 Q4 | 4.63 Million EUR | -11.46% |
| 2010 Q1 | 3.05 Million EUR | -11.21% |
| 2010 Q4 | 3.48 Million EUR | 9.75% |
| 2010 Q3 | 3.17 Million EUR | 4.57% |
| 2010 Q2 | 3.03 Million EUR | -0.56% |
| 2010 FY | 12.76 Million EUR | 9.26% |
| 2009 Q3 | 2.87 Million EUR | 3.91% |
| 2009 FY | 11.68 Million EUR | -14.36% |
| 2009 Q1 | 2.6 Million EUR | 0.0% |
| 2009 Q2 | 2.76 Million EUR | 6.23% |
| 2009 Q4 | 3.44 Million EUR | 19.85% |
| 2008 FY | 13.63 Million EUR | 386.93% |
| 2007 FY | -4.75 Million EUR | 1.47% |
| 2006 FY | -4.82 Million EUR | 42.09% |
| 2005 FY | -8.33 Million EUR | -8.25% |
| 2004 FY | -7.69 Million EUR | -823.77% |
| 2003 FY | -833 Thousand EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Bio Medica Corporation | 1.04 Million USD | -355.753% |
| Arrayit Corporation | 6.19 Million USD | 22.859% |
| Atlantic International Corp. | 5.57 Million USD | 14.295% |
| Biocept, Inc. | 29.4 Million USD | 83.739% |
| Bioqual, Inc. | 7.44 Million USD | 35.817% |
| CardioGenics Holdings Inc | 772.14 Thousand USD | -519.167% |
| DermTech, Inc. | 104.01 Million USD | 95.404% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 166.5 Million USD | 97.129% |
| HTG Molecular Diagnostics, Inc. | 22.62 Million USD | 78.868% |
| iMD Companies, Inc. | 151.8 Thousand USD | -3049.255% |
| IDenta Corp. | 662.97 Thousand USD | -621.121% |
| Interpace Biosciences, Inc. | 20.23 Million USD | 76.37% |
| Integrative Health Technologies, Inc. | 38.88 Thousand USD | -12196.114% |
| InVitro International | 661.32 Thousand USD | -622.921% |
| Lumos Diagnostics Holdings Limited | 7.09 Million USD | 32.645% |
| Many Bright Ideas Technologies Inc. | 58.11 Thousand USD | -8126.962% |
| Medical Imaging Corp. | 1.91 Million USD | -150.023% |
| NovelStem International Corp. | 3.53 Million USD | -35.136% |
| Optigenex Inc. | 1.28 Million USD | -271.222% |
| PharmChem, Inc. | 2.93 Million USD | -63.101% |
| Proteome Sciences plc | 3.26 Million USD | -46.293% |
| Response Genetics, Inc | 25.31 Million USD | 81.118% |
| Rennova Health, Inc. | 7.67 Million USD | 37.731% |
| RushNet, Inc. | 1.78 Million USD | -167.188% |
| ScreenPro Security Inc. | 3.23 Million USD | -47.607% |
| Stella Diagnostics Inc. | 11.42 Million USD | 58.162% |
| StageZero Life Sciences Ltd. | 7.34 Million USD | 34.893% |
| Todos Medical Ltd. | 14.05 Million USD | 65.992% |